Can transrectal ultrasonography distinguish anorectal malignant melanoma from low rectal adenocarcinoma? A retrospective paired study for ten years

Jingwen Yan†, Jigang Jing†, Shuang Wu, Lacong Geiru and Hua Zhuang*

Abstract

Background: Anorectal malignant melanoma (ARMM) and low rectal adenocarcinoma (LRAC) have some similarities in clinical behaviors, histopathological characteristics and ultrasonographic findings, diagnostic errors are common. By comparing the transrectally ultrasonographic features between the two tumors, we propose to provide more possibilities in differentiating them.

Methods: The data of 9 ARMMs and 27 age- and gender-matched LRACs (the lower margin below the peritoneal reflection) in West China Hospital Sichuan University between April 2008 and July 2019 were retrospectively reviewed. The ultrasonic features between the two groups were compared.

Results: Transrectal ultrasonography (TRUS) showed that the length of ARMM was shorter than that of LRAC (28.22 ± 12.29 mm vs. 40.22 ± 15.16 mm), and ARMM had a lower position than that of LRAC (the distance to anal verge was 50.78 ± 11.70 vs. 63.81 ± 18.73 mm). Unlike LRAC, the majority of ARMM in our study was confined to the intestinal mucosa/submucosa (66.67/25.93%) (**P < 0.05**).

Conclusions: Based on the data of our study, several ultrasonographic findings (length, invasion depth, and position) of ARMM were significantly different from LRAC. Accordingly, more attention should be paid to masses at anorectal junction with lower position, shorter length, and shallower infiltration depth. Instead of the most common tumor, LRAC, ARMM should be taken into account to avoid a misdiagnosis, which will result in a poorer prognosis.

Keywords: Diagnosis, Anorectal malignant melanoma, Low rectal adenocarcinoma, Transrectal ultrasonography

Background

Primary anorectal malignant melanoma (ARMM) is a rare disease, with an annual incidence less than 0.3 per million in the USA [1]. The prevalence has been increasing from 6.99% in 2004 to 10.53% in 2015 [2]. Owing to its non-specific symptoms and clinical signs, early diagnosis of ARMM is very difficult, and it is inclined to be misdiagnosed as anorectal cancer or hemorrhoids. It was reported that the misdiagnosis rate could be up to 80% (mainly as anorectal cancer) [3]. Adenocarcinoma is the most common type of low rectal malignant tumors. Approximately 30% of ARMM is amelanotic and can endoscopically resemble poorly differentiated adenocarcinoma, contributing to the difficulty in diagnosis [4]. Although there are some similarities between ARMM and low rectal adenocarcinoma (LRAC), their prognosis and treatments are different. ARMM is more aggressive.
At the time of diagnosis, 61% of patients with ARMM already have distant metastases, leading to a poor prognosis, with a median post-treatment survival time of 12–20 months and a 5-year survival rate of 6–22% [3, 5–10]. So, it is extremely imperative to reduce the misdiagnosis rate as well as the delay in timely treatments.

At present, transrectal ultrasonography (TRUS) is an important imaging method for preoperative evaluation of anorectal diseases. As most commonly malignant anorectal tumors are LRACs, the ultrasonographic manifestations reported in the literature have mainly been focused on rectal cancer. There has been no study reported on the differential diagnosis of ARMM and LRAC based on ultrasonographic features. We retrospectively collected and analyzed the data in our hospital, trying to provide the possibility of differentiating ARMM from LRAC by comparing the transrectally ultrasonic features of both tumors.

**Methods**

**Patients**

This retrospective study was approved by the Ethics Committee of West China Hospital, Sichuan University. Written informed consents were obtained from all patients. From April 2008 to July 2019, the date of 9 patients with ARMM who had undergone TRUS scanning before treatments were collected in our institution. Seven women and 2 men were included. The age of the 9 patients ranged from 59 to 69 years (65.33 ± 3.23 years). All patients underwent colonoscopy and biopsy, of whom four lesions were black and were diagnosed as ARMM. Two were suggested colorectal cancer due to the lack of tumor pigmentation. And the remaining three cases were diagnosed as colorectal cancer, but the color of these lesions were not recorded. The initial misdiagnosis rate reached 55.56% before postoperative pathological diagnosis and immunohistochemistry analysis. In our database during the corresponding period, 27 gender- and age-matched cases pathologically diagnosed with LRAC were randomly selected, every patient of this group also underwent colonoscopy and biopsy, all were suggested adenocarcinoma.

**Ultrasound evaluation**

TRUS was performed by MyLab Twice (Esaote, Genova, Italy) or Hivision Preirus (HITACHI, Tokyo, Japan) equipped with a biplane endoscopic probe (TRT33, linear frequency of 4–13 MHz, convex frequency of 3–9 MHz; EUP-R54AW-33, linear frequency of 4–15 MHz, convex frequency of 3–9 MHz, respectively), which was operated by two sonographers with at least 5 years of experience and were randomly assigned per the hospital’s daily schedule. We retrospectively analyzed all the 36 TRUS reports from our institution of the two groups. The ultrasound images were reviewed to record the lesion location, length, echotexture (homogeneous/heterogeneous), thickness, depth of invasion (DOI), the distance from the midpoint/the inferior border of the tumor to the anal verge along the long axis (M-Dist/I-Dist), the presence of lymph node metastasis, the size of these lymph nodes, blood flow signal, peak systolic velocity (PSV), and resistance index (RI).

According to the location of the tumor midpoint along the short axis of tumor, the patients were divided into the anterior wall group (A-group, lithotomy position, 10–2 o’clock) and non-anterior-group (NA-group, lithotomy position, other locations). On the basis of the DOI, patients were divided into shallow (mucosa-submucosa) group and deep (muscularis propria-adventitia) group. Meanwhile, we use the M-dist to compare the position of tumor (low/high).

**Statistical analysis**

Statistical package for social analysis (SPSS for Windows, IBM Corp, USA) version 25.0 was used for data analysis. Data were presented as mean ± standard deviation (SD), frequency, and percent. For statistical analysis, we used Student’s t-test for continuous variables, and two-tailed Fisher’s exact test for categorical variables. P values < 0.05 are considered statistically significant for all tests.

**Results**

According to the TRUS reports of the 36 patients, the mean value of the length of ARMM was shorter than that of LRAC (P = 0.037). Compared with LRAC, the position of ARMM tended to be lower, and the DOI of ARMM is shallower (P = 0.028, 0.046). Meanwhile, four and 16 patients had perirectal lymph node metastasis in ARMM and LRAC group. We found a total of 7 cases and 24 cases that were detected arterial pulse spectrum in ARMM and LRAC group. However, there were no significant differences in thickness, echotexture, location, PSV, RI, the presence of lymph node metastasis and the size of these lymph nodes. A summary of these results is shown in Table 1. Figures 1 and 2 depict the typical ultrasonic manifestations of ARMM.

**Discussion**

Primary malignant melanoma, with up to 1–2% of all malignant tumors, may occur on various sites of the body. Anorectum is the third most common location after skin and retina [11], accounting for 1% of melanomas and 0.5% of anorectal malignancies [12], which was first reported in 1857 by Moore [13]. Although over 150 years have passed, there is not much evidence for standard diagnostic and therapeutic methods due to...
Table 1 TRUS features of ARMM and LRAC

| Features | ARMM (n = 9) | LRAC (n = 27) | P |
|----------|--------------|---------------|---|
| L (mean ± SD, mm) | 28.22 ± 12.29 | 40.22 ± 15.16 | 0.037 |
| T (mean ± SD, mm) | 14.63 ± 6.73 | 15.75 ± 7.33 | 0.699 |
| M-Dist (mean ± SD, mm) | 50.78 ± 11.70 | 63.81 ± 18.73 | 0.028 |
| I-Dist (mean ± SD, mm) | 36.67 ± 8.82 | 43.44 ± 19.60 | 0.181 |
| DOI n (%) | 0.046 |
| Shallow | 6(66.67) | 7 (25.93) | |
| Deep | 3(33.33) | 20 (74.07) | |
| PSV (cm/s) | 31.40 ± 25.56 | 34.3 ± 22.91 | 0.547 |
| RI | 0.77 ± 0.14 | 0.83 ± 0.13 | 0.416 |
| Location n (%) | 0.255 |
| A | 6(66.67) | 11 (40.74) | |
| NA | 3(33.33) | 16 (59.26) | |
| Echotexture, n (%) | 0.148 |
| Homogeneous | 7(77.78) | 26 (96.30) | |
| Heterogeneous | 2 (22.22) | 10 (37.0) | |
| LN metastasis, n (%) | 4(44.44) | 16 (59.26) | 0.470 |
| Maximum diameter of LN (mm) | 10.25 ± 6.80 | 6.25 ± 1.75 | 0.384 |

TRUS: Transrectal ultrasoundography. ARMM: Anorectal malignant melanoma. LRAC: Low rectal adenocarcinoma. L: length. T: Thickness. M-Dist: the distance between the inferior border of tumor and the anal verge. I-Dist: the distance between the tumor midpoint and the anal verge. DOI: depth of invasion. Shallow: mucosa-submucosa invasion. Deep: muscularis propria-adventitia invasion. LN metastasis: the presence of lymph node metastasis. Maximum diameter of LN: the maximum diameter of metastatic lymph node. SD: Standard deviation. Bold indicates statistical significance.
Zhang et al. [35] enrolled 216 cases of ARMM, summarized the characteristics of these patients and described that the diameter of the tumor was relatively small (the average tumor size was 33 ± 21 mm). Other literature has reported that the median tumor size at initial presentation is between 20 and 50 mm, and Quan found that the size of lesions were < 10 mm in 25% of cases [6, 7, 26, 37, 38]. Meanwhile, there are some reports describing the mean diameter is relatively large of rectal cancer. Feng et al. [39] reported that the lesion diameter of 699 rectal cancer was 44.2 ± 17.3 mm. In our study, the mean length of ARMM (28.22 ± 12.29 mm) was shorter than that of LRAC (40.22 ± 15.16 mm) ultrasonically, which was statistically significant, the reason for it could be that most of the lesions in ARMM showed nodular or massive thickening of the intestinal wall with relatively regular shape, while most of the rectal cancer usually surrounds the intestinal wall and grows irregularly in the depth and length.

The staging of ARMM is different from the cutaneous melanoma. Most researches used the clinical staging, stage I tumors represent localized disease only, stage II regional lymph node involvement and stage III distant metastases [16, 40, 41]. This type of staging system does not take the DOI of tumor into consideration. Some publications have suggested a poorer prognosis with increasing DOI, especially in the muscular layer [36, 42, 43]. According to previous reports, only 11% to 18% of ARMM are confined to the mucosa/anal epithelium [36, 44], between 11 and 29% infiltrate into the submucosa, and about 79% invade the muscularis. It was shown that 44% patients of ARMM already have lymph node metastasis when the tumor infiltrate into the submucosa [43]. In our study, according to pathological verification after
surgery, three cases with ARMM were confined to the mucosa, three cases were limited to the submucosa, one case invaded muscularis propria, and two cases extended to the adventitia layer. Compared with postoperative pathology, the accuracy rate of TRUS in assessing the DOI was 77.8%. DOI of the 9 cases of ARMM in this article was relatively shallow compared to the above reports. None of the five patients of ARMM with complete date showed lymph node metastasis in other parts of the body (except for perirectal lymph node) and distant metastasis verified by the clinical, radiological assessment at the time of surgery, which may be due to the earlier consultation and diagnosis time. Most of the LRAC in our study broke through the submucosa and invaded the muscularis propria and adventitia layer (74.07%) ultrasonically, which only accounted for 22.22% in ARMM group. It may help us differentiate between these two diseases.

From our results, it is tough to distinguish ARMM and LRAC by a single feature on TRUS, but adding multiple findings may help in differentiation. According to some published literature, magnetic resonance imaging (MRI) also plays a role in the differential diagnosis of LRAC and ARMM, LRAC is characterized by thickening of the intestinal wall, an eccentrically lobulated tumor in the intestinal lumen, and the tumor usually manifests as iso/hyperintense on T1-weighted images and slightly hypointense on T2-weighted images, while the ARMM usually appears as a bulky intraluminal polyloid mass in the anorectum without colonic obstruction, and the mass shows hyperintense on T1-weighted images and hypointense on T2-weighted images due to the paramagnetic contribution from melanin, however, these features may be absent in patients who have amelanotic melanoma, which creates difficulties in the differential diagnosis of ARMM and LRAC [45–47]. Our study included the cases of a long time because the rarity of ARMM with a very small sample size, moreover, some patients are unable to have an MRI examination, making the contrast-enhanced

---

**Fig. 2** The ultrasonic image of an ARMM. A 61-year-old female patient. A A hypoechoic nodule of rectal wall was observed. B Punctate blood flow signals were detected in the nodule. C LOW resistance arterial spectrum was detected, and PSV was 14.9 cm/s, RI was 0.56. D The real-time elastography and strain ratio of the tissue around the intestinal wall to the lesion was 29.67. Immunohistochemistry analysis and pathology after surgery: HMB45 (+), S100 (+), PCK (−), MART1 (+), KI67 45%. Both ultrasound and pathology showed that the DOI was mucosa.
ultrasound (CEUS) and MRI results unavailable, so no significant differences were detected in other findings, which can be further studied in larger samples in the future.

Although Computed tomography, MRI, positron emission tomography and endoscopic ultrasound can be used to assess the location, size and DOI of anorectal masses, TRUS is convenient, fast, real-time, anesthesia-free, dynamic and cheap, thus it has been widely used in the examination of anorectal space-occupying lesions. Furthermore, the lower position and smaller size of ARMM make it unusual to be obstructing [48], especially suitable for TRUS.

Conclusions

In summary, TRUS provides necessary information for the initial assessment of anorectal masses, which could be useful for differential diagnosis on ARMM from the most ordinary anorectal malignancy, LRAC before surgery. Accordingly, compared with LRAC, most ARMM might manifest as relatively short length, low position and shallow DOI ultrasonically.

Abbreviations

ARMM: Anorectal malignant melanoma; LRAC: Low rectal adenocarcinoma; TRUS: Transrectal ultrasonography; DOI: Depth of invasion; PSV: Peak systolic velocity; RI: Resistance index; M-Dist: The distance between the tumor midpoint and the anal verge; I-Dist: The distance between the inferior border of tumor and the anal verge; CEUS: Contrast-enhanced ultrasound; MRI: Magnetic resonance imaging.

Author contributions

Jingwen Yan was responsible for data curation, investigation, and original manuscript drafting. Jigang Jing was responsible for revising manuscript, Jingwen Yan and Jigang Jing contributed equally to the work; Hua Zhuang was responsible for data curation and original manuscript drafting; Lacong Geiru was responsible for data curation; Jingwen Yan was responsible for data curation, investigation, and original manuscript drafting; Jigang Jing was responsible for revising manuscript, all authors read and approved the final manuscript.

Funding

The study was supported by Sichuan Science and Technology Planning Project, China (No. 21YYJC2467).

Availability data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Because our study involved patients with anorectal melanoma, a rare disease with only 9 cases in 10 years, all of their data were included in our hospital’s database, and for keeping track of their disease progression, these patients’ names, contact information and addresses have not been blurred in our database. The data of these patients are also valuable information for our hospital, so we didn’t choose to make all of these data public in the Data Availability Statement, but if scholars need our data, they can contact our corresponding author, we will be pleased to provide the complete data to help patients with this disease.

Declarations

Ethics approval and consent to participate

The study was conducted in compliance with the Declaration of Helsinki. This retrospective study was approved by the Ethics Committee of West China Hospital, Sichuan University (Registration Number ChiCTR-RNC-10000932).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have nothing to disclose.

Received: 22 July 2021 Accepted: 24 March 2022 Published online: 05 April 2022

References

1. Yang HM, Hsiao SJ, Schaeffer DF, Lai C, Remotti HE, Horst D, Mansukhani MM, Horst BA. Identification of recurrent mutational events in anorectal melanoma. Mod Pathol. 2017;30(2):286–96.
2. Taylor JP, Stern M, Yu D, Chen SY, Fang SH, Gearhart SL, Saffar B, Efron JE. Treatment strategies and survival trends for anorectal melanoma: is it time for a change? World J Surg. 2019;43(7):1809–19.
3. Pessaux P, Pocard M, Elias D, Duivillard P, Avril MF, Zimmerman P, Lasser P. Surgical management of primary anorectal melanoma. Br J Surg. 2004;91(9):1183–7.
4. Sahoo MR, Gouda MS, Kaladagi RM. Primary amelanotic melanoma of the rectum mimicking adenocarcinoma. Am J Case Rep. 2013;14:280–3.
5. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer-Am Cancer Soc. 2015;83(8):1664–78.
6. Brady MS, Kavloupis JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum. 1995;38(2):146–51.
7. Goldman S, Glimerelus B, Pahlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum. 1990;33(10):874–7.
8. Ross M, Pezzi C, Pezzi T, Meurer D, Hickey R, Balch C. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg. 1990;125(3):313–6.
9. Weinstock MA. Epidemiology and prognosis of anorectal melanoma. Gastroenterology. 1993;104(1):174–8.
10. Thibault C, Sagar P, Nivatvongs S, Listrup DM, Wolff BG. Anorectal melano-ma—an incurable disease? Dis Colon Rectum. 1997;40(6):661–8.
11. Hussein MR. Extrapancreatic malignant melanomas. Cancer Invest. 2008;26(5):516–34.
12. Ulmer A, Metzger S, Flierbeck G. Successful palliation of stenosing ano-rectal melanoma by intratumoral injections with natural interferon-beta. Melanoma Res. 2002;12(4):395–8.
13. Moore W. Recurrent melanosis of the rectum after previous removal from the verge of the anus in a man aged sixty-five. Lancet, 1
14. Falch C, Stojadinovic A, Hans-von-Weyhern C, Pratik M, Nissan A, Faries MB, Daumer M, Blichik AJ, Izhak A, Brucher BL. Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg. 2013;217(2):324–35.
15. Das G, Gupta S, Shukla PI, Jagannath P. Anorectal melanoma: a large clinicopathologic study from India. INT SURG. 2003;88(1):21–4.
16. Roumen RM. Anorectal melanoma in The Netherlands: a report of 63 patients. Eur J Surg Oncol. 1996;22(6):598–601.
17. Zhang S, Gao F, Wan D. Effect of misdiagnosis on the prognosis of anorectal malignant melanoma. J Cancer Res Clin Oncol. 2010;136(9):1401–5.
18. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.